1. Home
  2. KINS vs VYGR Comparison

KINS vs VYGR Comparison

Compare KINS & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KINS

Kingstone Companies Inc.

HOLD

Current Price

$15.83

Market Cap

205.7M

Sector

Finance

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.80

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KINS
VYGR
Founded
1886
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.7M
227.2M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
KINS
VYGR
Price
$15.83
$3.80
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.50
AVG Volume (30 Days)
127.2K
511.1K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
1.18%
N/A
EPS Growth
94.59
N/A
EPS
N/A
N/A
Revenue
$214,867,301.00
$10,135,000.00
Revenue This Year
$24.23
$34.04
Revenue Next Year
$18.05
$7.92
P/E Ratio
N/A
N/A
Revenue Growth
38.50
N/A
52 Week Low
$13.08
$2.65
52 Week High
$19.42
$5.55

Technical Indicators

Market Signals
Indicator
KINS
VYGR
Relative Strength Index (RSI) 51.19 47.93
Support Level $15.64 $3.71
Resistance Level $17.28 $4.39
Average True Range (ATR) 0.75 0.27
MACD 0.04 -0.03
Stochastic Oscillator 72.57 40.23

Price Performance

Historical Comparison
KINS
VYGR

About KINS Kingstone Companies Inc.

Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Share on Social Networks: